What is the significance of the Credit Agreement amendment for investors?

The amendment extends the company's credit facility by an additional 364 days, providing Boston Scientific with continued financial flexibility and access to capital for at least another year. This is important for funding operations, potential acquisitions, or managing existing debt.

Why did Boston Scientific increase fees on its Credit Agreement?

While the filing does not specify the exact reasons, increases in fees often accompany extensions or modifications of credit agreements. These could be related to market conditions, the extended duration, or specific terms negotiated with the lenders. Investors should monitor the overall cost of debt.

What is the financial impact of Fredericus Colen's promotion and incentive award?

The promotion itself does not immediately impact the company's financials beyond ongoing compensation. The long-term incentive awards (stock options and deferred stock units) represent a future potential dilution and expense to the company, depending on the vesting and exercise of these awards. These awards are designed to align executive interests with shareholder value over the long term.

Are the stock options and deferred stock units for Mr. Colen exercisable immediately?

No, the stock options and deferred stock units are subject to vesting schedules. The options vest in four equal annual installments starting one year from the grant date, and the deferred stock units will be issued in five equal annual installments starting one year from the grant date.

BSX 8-K: Leadership Changes & Material Agreements

Summary

Boston Scientific Corporation (BSX) filed an 8-K on August 1, 2008, detailing two key events that occurred on July 29, 2008. Firstly, the company entered into a material definitive agreement to amend its existing Credit Agreement. This amendment extends the term of the credit facility by 364 days and also involves an increase in certain fees. This extension provides BSX with continued access to financing for an additional year, which is a crucial aspect for ongoing operations and strategic initiatives. Secondly, the company announced an executive promotion, with Fredericus Colen appointed as Executive Vice President and President, CRM. In conjunction with his promotion, Mr. Colen's compensation package was adjusted. While his base salary and bonus incentive target remain unchanged, he received a long-term incentive award. This award includes stock options for 189,220 shares and a deferred stock unit award of 22,917 shares, vesting over several years. These executive compensation adjustments are standard practice for significant promotions and signal the company's commitment to retaining and incentivizing key leadership talent. Investors should note that these events, particularly the credit agreement amendment, suggest a focus on maintaining financial flexibility and supporting leadership development within the company.

Key Highlights

1Boston Scientific amended its Amended and Restated Credit and Security Agreement, extending its term by 364 days.
2The amendment to the Credit Agreement also includes an increase in certain fees payable by the company.
3Fredericus Colen was promoted to Executive Vice President and President, CRM.
4Mr. Colen's base salary and bonus incentive target will remain the same following his promotion.
5Mr. Colen received a long-term incentive award consisting of 189,220 stock options, vesting over four years.
6Mr. Colen also received a deferred stock unit award of 22,917 shares, vesting over five years.
7Both stock option and deferred stock unit awards were made under existing company long-term incentive plans.

BOSTON SCIENTIFIC CORP 8-K Report, Material Agreement (Aug 1, 2008)

Summary

Key Highlights

Frequently Asked Questions